Table 2.

Changes from baseline in lipid measures following evolocumab

Lipid profile	Overall (n = 151) M (± SD)	Non-DM (n = 68) M (± SD)	DM (n = 83) M (± SD)	P value
Baseline LDL	4.56 (± 2.46)	5.13 (± 3.26)	4.09 (± 1.37)	0.016
Post evolocumab (first follow-up)	3.00 (± 2.54)	3.66 (± 3.34)	2.47 (± 1.45)	0.008
Change in LDL	1.55 (± 1.53)	1.47 (± 1.38)	1.62 (± 1.64)	0.555
Percent change in LDL	34.73 (± 36.55)	31.42 (± 39.82)	37.45 (± 33.63)	0.369 *
Baseline TC	6.19 (± 2.35)	6.56 (± 2.93)	5.90 (± 1.68)	0.101
Post evolocumab (first follow-up) TC	4.66 (± 2.54)	5.30 (± 3.30)	4.13 (± 1.53)	0.008
Change in TC	1.54 (± 2.15)	1.27 (± 2.44)	1.77 (± 1.86)	0.154
Baseline HDL	1.06 (± 0.29)	1.10 (± 0.35)	1.02 (± 0.22)	0.098
Post evolocumab (first follow-up) HDL	1.06 (± 0.29)	1.11 (± 0.32)	1.01 (± 0.25)	0.076
Change in HDL	0.002 (± 0.22)	− 0.001 (± 0.23)	0.004 (± 0.20)	0.879
Baseline TG	2.16 (± 1.43)	1.84 (± 1.37)	2.42 (± 1.44)	0.012
Post evolocumab (first follow-up) TG	1.77 (± 1.19)	1.56 (± 1.31)	1.95 (± 1.10)	0.046
Change in TG	0.39 (± 1.25)	0.28 (± 0.95)	0.48 (± 1.45)	0.343

*Wilcoxon test, all others were Student-t test, DM: diabetes mellitus, NDM: none diabetes mellitus